Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose naproxen sodium + caffeine for postsurgical dental pain
2022-003274-22Phase 3
- Sponsor
- Bayer
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Aprol and caffeine in odontalgia and postoperative pain (4 arms), sponsored by Bayer. Primary endpoint: SPID0-8.
02
Drugs
Aprolcaffeine
03
Conditions
odontalgiapostoperative pain
Beyond the preview
Go deeper on 2022-003274-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003274-22.